Call for Abstract
International conference on Dementia and Alzheimer disease, will be organized around the theme “Exploring the Challenges and Excellence in Dementia Research”
Dementia 2021 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Dementia 2021
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Dementia is a chronic or persistent disorder of the mental ability process caused by brain diseases or injuries marked due to personality changes, memory disorders and impaired reasoning. Dementia is not a specific disease. It's a group of symptoms related with a decline in memory or other thinking ability skills enough to reduce a person's ability activities. Various kinds of dementia are associated with particular types of brain cell damage in particular regions of the brain
- Communication and language
- Ability to focus and pay attention
- Reasoning and judgment
- Visual perception
Vascular dementia, which occurs after a stroke, is the second most common dementia type. But there are many other conditions that can cause symptoms of dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Thinking problems also may begin as mild changes that worsen gradually as a result of multiple minor strokes or other conditions that affect smaller blood vessels, leading to cumulative damage. Vascular dementia symptoms can vary widely, depending on the severity of the blood vessel damage and the part of the brain affected. Memory loss may or may not be a significant symptom depending on the specific brain areas where blood flow is reduced. Symptoms may be most obvious when they happen soon after a major stroke
Dementia in “stages,” refers how far a person’s dementia has been progressed. It defines a person’s disease stage helping physicians to determine the best treatment approach and aid communication between health providers and caregivers. Sometimes the stage is simply referred to as “early stage”, “middle stage” or “late-stage” dementia, but often a more exact stage is assigned, based on a person’s symptoms.
- Global Deterioration Scale for Assessment of Primary Degenerative Dementia (GDS)
- Cognitive Decline
- Very Mild Cognitive Decline
- Mild Cognitive Decline
- Moderate Cognitive Decline
- Moderately Severe Cognitive Decline
- Severe Cognitive Decline (Middle Dementia
Neuro-oncology is the study of brain and spinal cord neoplasms, many of which are very dangerous and life-threatening (astrocytoma, glioma, glioblastoma multiforme, ependymoma, pontine glioma, and brain stem tumors are among the many examples of these). Among the malignant brain cancers, gliomas of the brainstem and pons, glioblastoma multiforme, and high-grade (highly anaplastic) astrocytoma are among the worst.The CNS consists of the brain and spinal cord. The brain is protected by the skull (the cranial cavity) and the spinal cord travels from the back of the brain, down the center of the spine, stopping in the lumbar region of the lower back. The brain and spinal cord are both housed within a protective triple-layered membrane called the meninges.
- Brain Stem Tumors
- Spine Diseases
- Malignant Brain Cancers and Brain Metastasis
- Pediatric Neuro Oncology
Neuropharmacology is the scientific study of the effects of drugs on the nervous system. Its primary focus is the actions of medications for psychiatric and neurologic disorders as well as those of drugs of abuse. Drugs that act on the nervous system, including antidepressant, antianxiety, anticonvulsant, and antipsychotic agents, are among the most widely prescribed medications.
Parkinson's disease (PD) is an age-related degenerative disorder of certain brain cells. It mainly affects movements of the body, but other problems, including dementia, may occur. It is not considered a hereditary disease, although a genetic link has been identified in a small number of families. Depression, anxiety, personality and behavior changes, sleep disturbances, and sexual problems are commonly associated with Parkinson's disease. In many cases, Parkinson's disease does not affect a person's ability to think, reason, learn, or remember (cognitive processes).
- Cardiovascular disease
The brain is the control center of the body. It controls thoughts, memory, speech, and movement. It regulates the function of many organs. When the brain is healthy, it works quickly and automatically. However, when problems occur, the results can be devastating. Inflammation in the brain can lead to problems such as vision loss, weakness and paralysis. Loss of brain cells, which happens if you suffer a stroke, can affect your ability to think clearly. Brain tumors can also press on nerves and affect brain function. Some brain diseases are genetic. And we do not know what causes some brain diseases, such as Alzheimer's disease.
- Huntington’s disease
- ALS (amyotrophic lateral sclerosis), or Lou Gehrig’s disease
- Parkinson’s disease
- Bipolar disorder
- Post-traumatic stress disorder (PTSD)
Neurodegenerative disease primarily affects the neurons in the human brain. Neurons are the building blocks of the nervous system which includes the brain and spinal cord. Neurons normally don’t reproduce or replace themselves, so when they become damaged or die they cannot be replaced by the body. Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and / or death of nerve cells. This causes problems with movement (called ataxias), or mental functioning (called dementias). Dementias are responsible for the greatest burden of neurodegenerative diseases, with Alzheimer’s representing approximately 60-70% of dementia cases.
- Alzheimer’s disease (AD) and other dementias
- Parkinson’s disease (PD) and PD-related disorders
- Prion disease
- Motor neurone diseases (MND)
- Huntington’s disease (HD)
- Spinocerebellar ataxia (SCA)
- Spinal muscular atrophy (SMA)
People with Lewy body dementia have a progressive decline in their memory and ability to think; similar to Alzheimer’s disease. However, the cognitive ability or alertness of a person with Lewy body dementia is more likely to fluctuate from one moment to the next, which is not like Alzheimer’s disease. They also often have visual hallucinations (seeing things that aren’t there) and delusions (believing something that is not true). On the surface, people with Lewy body dementia often have problems with movement that resemble Parkinson’s disease. This is because the same structures of the brain are affected in Lewy body dementia and Parkinson’s disease.
- Causes of Lewy Body Dementia
- Symptoms of Lewy Body Dementia
- Diagnosing Lewy Body
- Dementia Cholinesterase Inhibitors
- Diagnosing dementia (general)
- Treating dementia
Alzheimer's Disease is irreversible and decimates cerebrum cells, making thinking capacity and memory weaken. Alzheimer's infection is a dynamic, degenerative mind ailment and the most widely recognized type of dementia, a gathering of brain disorders that influence a man's memory, considering and capacity to connect socially. Dementia and Alzheimer's infection isn’t the same. Dementia is a general term used to depict indications that effect memory, execution of day by day exercises, and correspondence capacities. Alzheimer's infection is the most widely recognized kind of dementia. Alzheimer's illness isn't a typical piece of maturing. We are leading exploration into the part of aggravation in Alzheimer's sickness to discover potential focuses for remedial mediation. The Dominantly Inherited Alzheimer Network is the main aim to discover biomarkers for Alzheimer's Diseases that are perceptible some time before the underlying clinical side effects. Members experience cerebrum checks and clinical evaluations and give blood and spinal liquid to explore. Presently utilizing hereditary linkage ways to deal with endeavor to distinguish these modifier qualities, which may give helpful focuses to the treatment of Alzheimer's sickness
Geriatrics or geriatric medication
2:Mild and Major Neurocognitive Disorder
Thorough clinical preliminaries on Dementia drugs are proceeding in USA and UK under the direction of Alzheimer's general public and it is accounted for that there is less support of individuals. The majority of medications are in second and third stages. The greater part of clinical preliminaries are done in explicit territories are amyloid beta plaques, the resistant framework, tau tangles. New drugs for Dementia being created in 2014/2015, 31% were named side effects adjusting. There are numerous advancements are going on in Drug disclosure of Dementia as old medicines can't stop the movement of Dementia. Most affiliations share their investigation on new drugs for Dementia in Dementia gatherings to get higher regard to their things. This will be unmistakably profitable to various geriatric specialists to update themselves with such prescriptions and advancing prospects by going to Dementia meetings. Such Dementia gatherings will assist scientists with knowing objective zones for Drug improvement in Dementia and work towards it and furthermore Dementia meetings show clinical preliminary meds and offers energy to find new methodologies in relieving Dementia.
• Development of Re-purposed Drugs
• Beta-amyloid Polymerization and Inflammation Inhibitor
• Prevention Trials
• Anticonvulsant Drugs for Treatment
• Vaccine Development against Beta-Amyloid
• Animal Models for Toxicology Studies
Alzheimer's disease Biomarkers, with emphasis on cerebrospinal fluid biomarkers of Neuroimaging-biomarkers allow an early diagnosis in preclinical stages of Alzheimer’s disease. Biomarker changes in patients with late-onset AD, including findings from studies using structural and functional magnetic resonance imaging (MRI), advanced MRI techniques (diffusion tensor imaging, magnetic resonance spectroscopy, perfusion), positron emission tomography with fluorodeoxyglucose, amyloid tracers, and other neurochemical tracers, and CSF protein levels. The dynamic measures of these imaging biomarkers are used to predict the disease progression in the early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials.
Molecular biological research has considerably deepened our understanding of the pathophysiological basis of Alzheimer's dementia. Considerable progress has been made in our understanding of the genetics and molecular biology of dementia. Some genetic risk factors have been identified so far, but only a small proportion of AD cases can be explained by specific gene mutations. Genes may be related to disease in two ways: through autosomal-dominant mutations, in themselves sufficient to cause the disease alternatively, gene variations (polymorphisms) may indirectly increase disease risk without being sufficient in themselves to cause the disorder.